Literature DB >> 19470716

Efficient elimination of nonstoichiometric enzyme inhibitors from HTS hit lists.

Michael Habig1, Anke Blechschmidt, Sigmar Dressler, Barbara Hess, Viral Patel, Andreas Billich, Christian Ostermeier, David Beer, Martin Klumpp.   

Abstract

High-throughput screening often identifies not only specific, stoichiometrically binding inhibitors but also undesired compounds that unspecifically interfere with the targeted activity by nonstoichiometrically binding, unfolding, and/or inactivating proteins. In this study, the effect of such unwanted inhibitors on several different enzyme targets was assessed based on screening results for over a million compounds. In particular, the shift in potency on variation of enzyme concentration was used as a means to identify nonstoichiometric inhibitors among the screening hits. These potency shifts depended on both compound structure and target enzyme. The approach was confirmed by statistical analysis of thousands of dose-response curves, which showed that the potency of competitive and therefore clearly stoichiometric inhibitors was not affected by increasing enzyme concentration. Light-scattering measurements of thermal protein unfolding further verified that compounds that stabilize protein structure by stoichiometric binding show the same potency irrespective of enzyme concentration. In summary, measuring inhibitor IC(50) values at different enzyme concentrations is a simple, cost-effective, and reliable method to identify and eliminate compounds that inhibit a specific target enzyme via nonstoichiometric mechanisms.

Mesh:

Substances:

Year:  2009        PMID: 19470716     DOI: 10.1177/1087057109336586

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  9 in total

1.  Using 'biased-privileged' scaffolds to identify lysine methyltransferase inhibitors.

Authors:  Sudhir Kashyap; Joel Sandler; Ulf Peters; Eduardo J Martinez; Tarun M Kapoor
Journal:  Bioorg Med Chem       Date:  2014-02-28       Impact factor: 3.641

2.  Supergenomic network compression and the discovery of EXP1 as a glutathione transferase inhibited by artesunate.

Authors:  Andreas Martin Lisewski; Joel P Quiros; Caroline L Ng; Anbu Karani Adikesavan; Kazutoyo Miura; Nagireddy Putluri; Richard T Eastman; Daniel Scanfeld; Sam J Regenbogen; Lindsey Altenhofen; Manuel Llinás; Arun Sreekumar; Carole Long; David A Fidock; Olivier Lichtarge
Journal:  Cell       Date:  2014-08-14       Impact factor: 41.582

3.  Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.

Authors:  Stephen Boulton; Rajeevan Selvaratnam; Rashik Ahmed; Katherine Van; Xiaodong Cheng; Giuseppe Melacini
Journal:  J Med Chem       Date:  2019-05-10       Impact factor: 7.446

4.  Modulation of pantothenate kinase 3 activity by small molecules that interact with the substrate/allosteric regulatory domain.

Authors:  Roberta Leonardi; Yong-Mei Zhang; Mi-Kyung Yun; Ruobing Zhou; Fu-Yue Zeng; Wenwei Lin; Jimmy Cui; Taosheng Chen; Charles O Rock; Stephen W White; Suzanne Jackowski
Journal:  Chem Biol       Date:  2010-08-27

Review 5.  Matching the power of high throughput screening to the chemical diversity of natural products.

Authors:  Curtis J Henrich; John A Beutler
Journal:  Nat Prod Rep       Date:  2013-08-08       Impact factor: 13.423

6.  Small-molecule active pharmaceutical ingredients of approved cancer therapeutics inhibit human aspartate/asparagine-β-hydroxylase.

Authors:  Lennart Brewitz; Anthony Tumber; Xiaojin Zhang; Christopher J Schofield
Journal:  Bioorg Med Chem       Date:  2020-08-06       Impact factor: 3.641

7.  Orally efficacious broad-spectrum allosteric inhibitor of paramyxovirus polymerase.

Authors:  Robert M Cox; Julien Sourimant; Mart Toots; Jeong-Joong Yoon; Satoshi Ikegame; Mugunthan Govindarajan; Ruth E Watkinson; Patricia Thibault; Negar Makhsous; Michelle J Lin; Jose R Marengo; Zachary Sticher; Alexander A Kolykhalov; Michael G Natchus; Alexander L Greninger; Benhur Lee; Richard K Plemper
Journal:  Nat Microbiol       Date:  2020-07-13       Impact factor: 17.745

Review 8.  Recent Advances in EPAC-Targeted Therapies: A Biophysical Perspective.

Authors:  Alveena Ahmed; Stephen Boulton; Hongzhao Shao; Madoka Akimoto; Amarnath Natarajan; Xiaodong Cheng; Giuseppe Melacini
Journal:  Cells       Date:  2019-11-19       Impact factor: 6.600

9.  Development of Tyrphostin Analogues to Study Inhibition of the Mycobacterium tuberculosis Pup Proteasome System*.

Authors:  Guido V Janssen; Susan Zhang; Remco Merkx; Christa Schiesswohl; Champak Chatterjee; K Heran Darwin; Paul P Geurink; Gerbrand J van der Heden van Noort; Huib Ovaa
Journal:  Chembiochem       Date:  2021-09-12       Impact factor: 3.164

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.